CNS Pharmaceuticals, Inc. CNSP
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
CNS Pharmaceuticals, Inc. (CNSP) is a healthcare company listed in the US with a market value of about $4M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -189%.
About CNS Pharmaceuticals
CNS Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. It was profitable in 0 of the last 8 years in our data. Its share count rose by 977573% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Net income | -$16M | -$15M | -$19M | -$15M | -$14M | -$9M | -$4M | -$7M |
| Free cash flow | -$14M | -$17M | -$14M | -$11M | -$14M | -$7M | -$4M | -$716385 |
| EPS (diluted) | $-35.75 | $-466.89 | $-150252.80 | $-336910.28 | $-495456.29 | $-17115.76 | $-8407.74 | $-21019.36 |
| Net margin | — | — | — | — | — | — | — | — |
| ROIC | -260.3% | -181.0% | — | -141.2% | -174.7% | -51.8% | -39.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does CNS Pharmaceuticals pay a dividend?
Not currently.
Is CNS Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. CNS Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.